Randomized, placebo controlled, patient and observer masked study to evaluate the efficacy of treatment with Sandostatin LAR 20 mg i.m. or placebo every 4 weeks during 6 months in 120 patients with exudative age-related macular degeneration.
Completed
- Registration Number
- NL-OMON25954
- Brief Summary
T.Missotten, G.S. Baarsma, R.W. A. M. Kuijpers, P.M. van Hagen. Somatostatin Analog for the Treatment of Exsudative Age Related Macular Degeneration: A Randomised Trial. ARVO 2007.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
1. Recent history of visual acuity decrease (< 6 weeks prior to study start) related to exudative ARMD;
2. Clinical signs of ARMD (i.e. drusen and/or RPE changes);
Exclusion Criteria
1. Diabetes mellitus;
2. Symptomatic cholelithiasis;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Visual acuity and contrast sensitivity,<br>decrease in macular edema and arrest of neovascularisation (FAG).
- Secondary Outcome Measures
Name Time Method